Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

138.55
-1.2200-0.87%
Post-market: 138.590.0400+0.03%19:44 EDT
Volume:3.43M
Turnover:475.85M
Market Cap:171.90B
PE:20.44
High:140.27
Open:138.61
Low:137.75
Close:139.77
52wk High:157.29
52wk Low:93.37
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.72
T/O Rate:0.28%
Dividend:3.16
Dividend Rate:2.28%
EPS(TTM):6.78
EPS(LYR):6.78
ROE:40.66%
ROA:12.52%
PB:7.57
PE(LYR):20.44

Loading ...

Gilead CFO Andrew Dickinson disposes 3,000 shares worth $422,880

Reuters
·
5 hours ago

Gilead Chief Comm & Corp Aff Officer Johanna Mercier sells 3,000 shares for $422,880

Reuters
·
5 hours ago

Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says

MT Newswires Live
·
Yesterday

Tango Therapeutics names Matthew Gall CFO, replacing Daniella Beckman

Reuters
·
Apr 15

Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)

TIPRANKS
·
Apr 15

Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target

TIPRANKS
·
Apr 15

Wells Fargo Sticks to Their Buy Rating for Gilead Sciences (GILD)

TIPRANKS
·
Apr 15

Gilead Sciences Inc. Stock Rises Tuesday, Still Underperforms Market

Dow Jones
·
Apr 15

Gilead announces investment in lenacapavir by PEPFAR, The Global Fund

TIPRANKS
·
Apr 15

Gilead - Lenacapavir Initial Shipments to Sub-Saharan Africa Expected End of 2025

THOMSON REUTERS
·
Apr 15

Gilead - Large-Scale Generic Rollout of Lenacapavir Expected to Start in 2027

THOMSON REUTERS
·
Apr 15

Pepfar and the Global Fund Make Additional Investment in Gilead’s Lenacapavir for Hiv Prevention to Further Expand Access

THOMSON REUTERS
·
Apr 15

Global Fund expands commitment to improve access to HIV drug

Reuters
·
Apr 15

Gilead Sciences Is Maintained at Buy by Citigroup

Dow Jones
·
Apr 14

Gilead put volume heavy and directionally bearish

TIPRANKS
·
Apr 14

Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating

MT Newswires Live
·
Apr 13

Big Yachts, Big Bucks -- Barrons.com

Dow Jones
·
Apr 11

Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
Apr 11

Gilead Sciences Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 10

Gilead price target raised to $175 from $171 at Morgan Stanley

TIPRANKS
·
Apr 10